Commentary
Commentary
It’s Time To Let The Electric Vehicle Industry Grow Up
The U.S. has been subsidizing electric vehicles (EVs) since 2009 and hybrid vehicles for even longer. Recent Congressional actions have substantially changed this policy. As part of the reconciliation package, Congress rolled back the $7,500 federal EV tax credit ($4,000 credit for used EVs) as well as the EV battery ...
Commentary
Time To Crack Down On The Knock-Off Weight-Loss Drug Trade
Wegovy, Zepbound, and other GLP-1 agonists have given Americans an extraordinary new tool for losing weight and improving their health. But they’ve also given rise to a dangerous new public health threat—counterfeit medicines. In a rush to capitalize on the popularity of these drugs, a number of third-party telehealth firms ...
Commentary
Should the Government Control Drug Prices? No…
In a May 12 executive order, President Trump announced a “most favored nation” policy that intends to lower prescription drug prices. Among other things, the order directed the Secretary of Health and Human Services to “communicate most-favored-nation price targets to pharmaceutical manufacturers to bring prices . . . in line ...
Commentary
Trump Embraces Disastrous Most Favored Nation Drug Pricing
President Donald Trump gave American drug companies an ultimatum last month. Either they agree to adopt foreign-style price controls, or the administration “will deploy every tool in [its] arsenal” to do it for them. More specifically, the president asked drug firms to base U.S. drug prices for a given drug ...
Business & Economics
Using The Government To Crush Competitors Harms Fans And The Economy
Cronyism and industrial policy are thriving to the detriment of our economic vibrancy. Consider that between 1960 and 2007 – right before the Great Recession – the economy expanded by more than 3% annually. Recessions happened, of course, but the economy always recovered the lost ground. Read the op-ed here.
Commentary
Tariffs Won’t Secure Our Drug Supply Chain—They’ll Break It
The Trump administration is considering massive “Section 232” tariffs on imported medicines from key U.S. allies, including the European Union, the United Kingdom, Switzerland, Japan, and South Korea. While tariffs on some countries, such as EU member states, could be capped at 15%, other tariffs could reportedly be set as ...
Commentary
The New Medicine Tariffs Are a Prescription for Disaster
President Trump has recently struck trade agreements with the European Union and Japan. Both deals will impose a 15 percent tariff on imported prescription drugs and active pharmaceutical ingredients. White House officials believe these tariffs will benefit Americans by nudging pharmaceutical companies to relocate their manufacturing operations stateside in order ...
Commentary
How innovation saves lives: What America’s pharmaceutical ecosystem gets right
When a woman is diagnosed with breast cancer in the United States today, her chances of surviving are much greater than in decades past — thanks to U.S. innovation. The incidence of breast cancer has increased by more than 200% globally in the past 40 years. But the U.S. mortality ...
Commentary
The rural hospital rescue fund is a fraud
Rural hospitals are supposedly in dire financial straits. And the forthcoming Medicaid “cuts” authorized by the One Big Beautiful Bill Act could put hundreds more facilities deep in the red. At least, that’s the prevailing narrative inside the beltway — and the justification for the $50 billion rural hospital “rescue” ...
Commentary
What’s The GLP-1 Black Market, How Big a Threat Is It?
A black market in weight-loss drugs is flourishing in plain sight. Rogue pharmacies and telehealth firms are flooding the United States with unauthorized knock-offs of semaglutide, tirzepatide, and other glucagon-like peptide-1 drugs. Better known by brand names like Ozempic, Wegovy, Mounjaro, and Zepbound, the knock-off versions of these drugs are ...
It’s Time To Let The Electric Vehicle Industry Grow Up
The U.S. has been subsidizing electric vehicles (EVs) since 2009 and hybrid vehicles for even longer. Recent Congressional actions have substantially changed this policy. As part of the reconciliation package, Congress rolled back the $7,500 federal EV tax credit ($4,000 credit for used EVs) as well as the EV battery ...
Time To Crack Down On The Knock-Off Weight-Loss Drug Trade
Wegovy, Zepbound, and other GLP-1 agonists have given Americans an extraordinary new tool for losing weight and improving their health. But they’ve also given rise to a dangerous new public health threat—counterfeit medicines. In a rush to capitalize on the popularity of these drugs, a number of third-party telehealth firms ...
Should the Government Control Drug Prices? No…
In a May 12 executive order, President Trump announced a “most favored nation” policy that intends to lower prescription drug prices. Among other things, the order directed the Secretary of Health and Human Services to “communicate most-favored-nation price targets to pharmaceutical manufacturers to bring prices . . . in line ...
Trump Embraces Disastrous Most Favored Nation Drug Pricing
President Donald Trump gave American drug companies an ultimatum last month. Either they agree to adopt foreign-style price controls, or the administration “will deploy every tool in [its] arsenal” to do it for them. More specifically, the president asked drug firms to base U.S. drug prices for a given drug ...
Using The Government To Crush Competitors Harms Fans And The Economy
Cronyism and industrial policy are thriving to the detriment of our economic vibrancy. Consider that between 1960 and 2007 – right before the Great Recession – the economy expanded by more than 3% annually. Recessions happened, of course, but the economy always recovered the lost ground. Read the op-ed here.
Tariffs Won’t Secure Our Drug Supply Chain—They’ll Break It
The Trump administration is considering massive “Section 232” tariffs on imported medicines from key U.S. allies, including the European Union, the United Kingdom, Switzerland, Japan, and South Korea. While tariffs on some countries, such as EU member states, could be capped at 15%, other tariffs could reportedly be set as ...
The New Medicine Tariffs Are a Prescription for Disaster
President Trump has recently struck trade agreements with the European Union and Japan. Both deals will impose a 15 percent tariff on imported prescription drugs and active pharmaceutical ingredients. White House officials believe these tariffs will benefit Americans by nudging pharmaceutical companies to relocate their manufacturing operations stateside in order ...
How innovation saves lives: What America’s pharmaceutical ecosystem gets right
When a woman is diagnosed with breast cancer in the United States today, her chances of surviving are much greater than in decades past — thanks to U.S. innovation. The incidence of breast cancer has increased by more than 200% globally in the past 40 years. But the U.S. mortality ...
The rural hospital rescue fund is a fraud
Rural hospitals are supposedly in dire financial straits. And the forthcoming Medicaid “cuts” authorized by the One Big Beautiful Bill Act could put hundreds more facilities deep in the red. At least, that’s the prevailing narrative inside the beltway — and the justification for the $50 billion rural hospital “rescue” ...
What’s The GLP-1 Black Market, How Big a Threat Is It?
A black market in weight-loss drugs is flourishing in plain sight. Rogue pharmacies and telehealth firms are flooding the United States with unauthorized knock-offs of semaglutide, tirzepatide, and other glucagon-like peptide-1 drugs. Better known by brand names like Ozempic, Wegovy, Mounjaro, and Zepbound, the knock-off versions of these drugs are ...
